← Back to patent-cliff list
Nab-rapamycin
Tier C — Watch / tradeNab-rapamycin
Abraxis Bioscience Inc
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mTOR, MCM
Brand：TARZIFYX, Fyarro
Indications (approved)：血管周上皮样细胞瘤
Regional status
US
Approved
2021-11-22
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nab-rapamycin?
Approved indications include: 血管周上皮样细胞瘤.
When does the Nab-rapamycin patent expire?
No public expiry year is available for Nab-rapamycin yet; this page updates once verified.
How do I get a quote for Nab-rapamycin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27